China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) Subsidiary Receives Drug Registration Certificate for Alfacalcidol Soft Capsules

Stock News10-20

China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. ("Wanhui Double-Crane"), has received a Drug Registration Certificate for Alfacalcidol Soft Capsules issued by the National Medical Products Administration. Alfacalcidol Soft Capsules are indicated for the treatment of calcium metabolism disorders due to insufficient endogenous 1,25-dihydroxyvitamin D3. Conditions treated include renal osteodystrophy, postoperative or idiopathic hypoparathyroidism, pseudohypoparathyroidism, as an adjunct treatment for tertiary hyperparathyroidism, vitamin D-resistant rickets or osteomalacia, vitamin D-dependent rickets, neonatal hypocalcemia or rickets, malabsorption syndromes, osteoporosis, malabsorption-related and nutritional rickets, and osteomalacia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147278412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147278412","market":"sh","top_or_hot":-1,"title":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) Subsidiary Receives Drug Registration Certificate for Alfacalcidol Soft Capsules","media":"Stock News","content":"<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. (\"Wanhui Double-Crane\"), has received a Drug Registration Certificate for Alfacalcidol Soft Capsules issued by the National Medical Products Administration. Alfacalcidol Soft Capsules are indicated for the treatment of calcium metabolism disorders due to insufficient endogenous 1,25-dihydroxyvitamin D3. Conditions treated include renal osteodystrophy, postoperative or idiopathic hypoparathyroidism, pseudohypoparathyroidism, as an adjunct treatment for tertiary hyperparathyroidism, vitamin D-resistant rickets or osteomalacia, vitamin D-dependent rickets, neonatal hypocalcemia or rickets, malabsorption syndromes, osteoporosis, malabsorption-related and nutritional rickets, and osteomalacia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) Subsidiary Receives Drug Registration Certificate for Alfacalcidol Soft Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) Subsidiary Receives Drug Registration Certificate for Alfacalcidol Soft Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-20 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. (\"Wanhui Double-Crane\"), has received a Drug Registration Certificate for Alfacalcidol Soft Capsules issued by the National Medical Products Administration. Alfacalcidol Soft Capsules are indicated for the treatment of calcium metabolism disorders due to insufficient endogenous 1,25-dihydroxyvitamin D3. Conditions treated include renal osteodystrophy, postoperative or idiopathic hypoparathyroidism, pseudohypoparathyroidism, as an adjunct treatment for tertiary hyperparathyroidism, vitamin D-resistant rickets or osteomalacia, vitamin D-dependent rickets, neonatal hypocalcemia or rickets, malabsorption syndromes, osteoporosis, malabsorption-related and nutritional rickets, and osteomalacia.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1147278412","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147278412","pubTimestamp":1760952877,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. (\"Wanhui Double-Crane\"), has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0028":"国家队","BK0188":"融资融券","BK0175":"白马股","BK0010":"央企","BK0239":"医药制造","BK0185":"二线龙头"},"translate_title":"华润双鹤药业（600062.SH）子公司获得阿法骨化醇软胶囊药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1},"content_text":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. (\"Wanhui Double-Crane\"), has received a Drug Registration Certificate for Alfacalcidol Soft Capsules issued by the National Medical Products Administration. Alfacalcidol Soft Capsules are indicated for the treatment of calcium metabolism disorders due to insufficient endogenous 1,25-dihydroxyvitamin D3. Conditions treated include renal osteodystrophy, postoperative or idiopathic hypoparathyroidism, pseudohypoparathyroidism, as an adjunct treatment for tertiary hyperparathyroidism, vitamin D-resistant rickets or osteomalacia, vitamin D-dependent rickets, neonatal hypocalcemia or rickets, malabsorption syndromes, osteoporosis, malabsorption-related and nutritional rickets, and osteomalacia.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147278412","isCrawlerRequest":true}